• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Emergency

Pathway modification reduces admissions for pediatric anaphylaxis

byKate AndersonandLeah Carr, MD
April 3, 2018
in Emergency, Pediatrics
Reading Time: 3 mins read
Pathway modification reduces admissions for pediatric anaphylaxis
Share on FacebookShare on Twitter

1. Inpatient and observation unit admissions for pediatric anaphylaxis decreased by more than half following implementation of a revised clinical care pathway.

2. More than 80% of patients were given an epinephrine autoinjector upon emergency department (ED) discharge following an anaphylactic attack.

Study Rundown: Anaphylaxis is a life-threatening allergic reaction, often related to food allergies, and is an increasingly common cause of ED visits among the pediatric population. Experts disagree on the optimal observation period after resolution of symptoms, with recommendations ranging from 3 to 24 hours. This variation results in increased hospitalizations and admissions to ED observation units. In this study, members of a multidisciplinary team revised an existing clinical care pathway for pediatric anaphylaxis to decrease the observation period from 8 hours to 4 hours, as well as to improve provider education about anaphylaxis treatment recommendations, and to increase the percent of anaphylaxis patients who leave the ED with an epinephrine autoinjector. After pathway revision, there was a >50% decrease in the number of admissions without an increase in the number of patients who returned to the ED within 72 hours for reasons related to the initial visit. There was no significant change in median time to first epinephrine dose (first-line treatment for anaphylaxis). More than 80% of patients were given an epinephrine autoinjector upon ED discharge. Limitations of this study included a lack of data regarding readmissions to EDs or urgent care centers outside the primary hospital’s network, nor did it collect baseline data regarding the number of patients receiving autoinjectors upon ED discharge prior to pathway revision. Results of this study suggest decreasing observation periods following pediatric anaphylaxis to 4 hours can safely and effectively decrease hospital admissions.

Click to read the study, published today in Pediatrics

Relevant reading: Food allergy among U.S. children: trends in prevalence and hospitalizations

In-depth [Quality Improvement]: Researchers from Children’s Hospital of Philadelphia analyzed data from 182 pediatric anaphylaxis cases seen prior to and 257 cases seen after revision of a clinical care pathway in the hospital’s ED. The pathway was updated in 2014 using input from a multidisciplinary team based on national expert opinions. Changes to the pathway included: decreasing the recommended post-treatment observation period from 8 to 4 hours; inserting a chart with anaphylaxis diagnostic criteria and highlighting epinephrine as the first-line treatment; and including a section reminding nurses to discharge patients with epinephrine autoinjectors. Results showed pathway revision resulted in a decrease in hospital or observation unit admissions from 58.2% to 25.3% (p < .0001), without a concurrent increase in patients returning to care within 72 hours for persistent anaphylaxis symptoms (1.3% vs. 2.6%, before and after revision respectively, p = .99). There was no significant change in the time to first epinephrine administration (median time 15 minutes and 10 minutes, respectively, p = .87). A total of 85.4% of patients discharged from the ED following anaphylaxis left with an epinephrine autoinjector in hand. The most frequently cited reason for patients not being given an autoinjector was that they already had one at home.

RELATED REPORTS

Uterine-Sparing Mesh Repair Outperforms Hysterectomy for Prolapse

Daraxonrasib showed antitumor activity in previously treated RAS-mutant non–small-cell lung cancer

The mortality in-hospital for patients undergoing elective catheter ablation for atrial fibrillation is low

Image: CC/Wiki/AngelHM

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Previous Post

2 Minute Medicine Rewind April 2, 2018

Next Post

All-cause mortality is increased for older adults with sudden loss of wealth in the US

RelatedReports

Similar outcomes after supracervical vs. total hysterectomy
Surgery

Uterine-Sparing Mesh Repair Outperforms Hysterectomy for Prolapse

September 4, 2026
Dacomitinib may be effective in EGFR-associated lung cancer
Oncology

Daraxonrasib showed antitumor activity in previously treated RAS-mutant non–small-cell lung cancer

September 4, 2026
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source
Cardiology

The mortality in-hospital for patients undergoing elective catheter ablation for atrial fibrillation is low

September 4, 2026
Rituximab linked with reduced chronic immune disease following stem cell transplantation
Hematology

Azacitidine–venetoclax improved event-free survival in induction-eligible AML

September 4, 2026
Next Post

All-cause mortality is increased for older adults with sudden loss of wealth in the US

Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors

Solid fuel use linked to increased cardiovascular and all-cause mortality

Meeting families, demographic information affect child abuse work-up

Acid suppression and antibiotic use in infancy linked to allergic disease

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Uterine-Sparing Mesh Repair Outperforms Hysterectomy for Prolapse
  • Daraxonrasib showed antitumor activity in previously treated RAS-mutant non–small-cell lung cancer
  • The mortality in-hospital for patients undergoing elective catheter ablation for atrial fibrillation is low
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.

2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in